[HTML][HTML] FUT8 and protein core fucosylation in tumours: from diagnosis to treatment
C Liao, J An, S Yi, Z Tan, H Wang, H Li, X Guan… - Journal of …, 2021 - ncbi.nlm.nih.gov
Glycosylation changes are key molecular events in tumorigenesis, progression and
glycosyltransferases play a vital role in the this process. FUT8 belongs to the …
glycosyltransferases play a vital role in the this process. FUT8 belongs to the …
Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics
S Tang, M Wang, Y Peng, Y Liang, J Lei… - Frontiers in …, 2024 - frontiersin.org
Armeniacae semen amarum—seeds of Prunus armeniaca L.(Rosaceae)(ASA), also known
as Kuxingren in Chinese, is a traditional Chinese herbal drug commonly used for lung …
as Kuxingren in Chinese, is a traditional Chinese herbal drug commonly used for lung …
AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study
In patients with HCC awaiting liver transplantation (LT), there is a need to identify
biomarkers that are superior to AFP in predicting prognosis. AFP-L3 and des-gamma …
biomarkers that are superior to AFP in predicting prognosis. AFP-L3 and des-gamma …
Prognostic value of CD8+ Lymphocytes in hepatocellular carcinoma and perineoplastic parenchyma assessed by interface density profiles in liver resection samples
R Stulpinas, D Zilenaite-Petrulaitiene, A Rasmusson… - Cancers, 2023 - mdpi.com
Simple Summary In this study, we present the overall survival and recurrence-free survival
models based on CD8 profiles in hepatocellular carcinoma (HCC) and peritumoral liver …
models based on CD8 profiles in hepatocellular carcinoma (HCC) and peritumoral liver …
Promising novel biomarkers for Hepatocellular carcinoma: diagnostic and prognostic insights
The systemic therapy landscape for hepatocellular carcinoma is rapidly evolving, as the
recent approvals of checkpoint inhibitor-based regimens such as atezolizumab …
recent approvals of checkpoint inhibitor-based regimens such as atezolizumab …
[HTML][HTML] Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment …
DA Dominguez, P Wong… - Hepatobiliary Surgery and …, 2024 - ncbi.nlm.nih.gov
Methods PubMed and Embase databases were searched using the keywords;
hepatocellular carcinoma, biomarker, minimal residual disease, surveillance, prognosis …
hepatocellular carcinoma, biomarker, minimal residual disease, surveillance, prognosis …
Baseline alpha-fetoprotein, alpha-fetoprotein-l3, and des-gamma-carboxy prothrombin biomarker status in bridge to liver transplant outcomes for hepatocellular …
Simple Summary An abnormal alpha-fetoprotein (AFP) test is often associated with
hepatocellular carcinoma (HCC) development, although as many as 40% of HCC diagnoses …
hepatocellular carcinoma (HCC) development, although as many as 40% of HCC diagnoses …
Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma
J Liu, K Park, Z Shen, H Lee, P Geetha… - Frontiers in …, 2023 - frontiersin.org
Hepatocellular carcinoma (HCC) is a challenging malignancy with limited treatment options
beyond surgery and chemotherapy. Recent advancements in targeted therapies and …
beyond surgery and chemotherapy. Recent advancements in targeted therapies and …
Hepatocellular Carcinoma Genetic Classification
Z Lominadze, MR Shaik, D Choi, D Zaffar… - The Cancer …, 2023 - journals.lww.com
Hepatocellular carcinoma (HCC) represents a significant global burden, with management
complicated by its heterogeneity, varying presentation, and relative resistance to therapy …
complicated by its heterogeneity, varying presentation, and relative resistance to therapy …
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
S Han, HJ Choi, SH Beom, HR Kim, H Lee… - Journal of cancer …, 2021 - Springer
Background We compared the clinical efficacies of hepatic arterial infusion chemotherapy
(HAIC) vs. sorafenib as sequential maintenance therapy following liver-directed concurrent …
(HAIC) vs. sorafenib as sequential maintenance therapy following liver-directed concurrent …